Meta AnalysisID 6318
芪苈强心胶囊联合西药治疗慢性心力衰竭的疗效和安全性：系统评价与Meta分析的研究方案
CRD42021224475
The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Qili Qiangxin Capsule combined with western medicine for chronic heart failure.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6318
- Evidence Id
- 14876
- Core Evidence Id
- 14876
- Source Meta Analysis Id
- 6303
- Herb2 Meta Analysis Id
- HBMA006303
- Crd Id
- CRD42021224475
- Title
- Efficacy and safety of Qili Qiangxin Capsule combined with western medicine in the treatment of chronic heart failure : Study protocol for systematic review and meta-analyses
- Review Question
- The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Qili Qiangxin Capsule combined with western medicine for chronic heart failure.
- Study Type Included
- Randomized controlled trials (RCTs) will be included
- Condition Being Studied
- Chronic heart failure is a serious heart disease with major clinical manifestations, such as dyspnea and limited mobility. The incidence rate is positively correlated with the duration and age. Qiliqiangxin capsule is a compound preparation for the treatment of chronic heart failure. Although clinical studies have shown that Qiliqiangxin capsule has obvious effect on patients with heart failure, it still lacks evidence-based medical support.
- Participant
- The patients were definitely diagnosed as chronic heart failure.
- Animal
- Human Disease Modelled
- Intervention
- Qiliqiangxin capsule was added to the routine treatment.
- Comparator Control
- Routine treatment with Western Medicine
- Main Outcome
- ① Evaluation of cardiac function; ② left ventricular ejection fraction (LVEF); ③ 6-minute walk test (6MWT); ④ NT-pro BNP Measures of effect RR / or was used as binary variable, SMD / MD as continuous variable, HR as survival analysis data
- Outcome Measure
- Additional Outcome
- MLHFQ and adverse reactions Measures of effect RR / or was used as binary variable, SMD / MD as continuous variable, HR as survival analysis data
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Drugs, Chinese Herbal; Heart Failure; Humans; qiangxin
- Contact
- SHUMIN HUANG [email protected]
- Organisational Affiliation
- 湖南中医药大学 https://www.hnucm.edu.cn/
- Funding Source
- The article was supported by the National Natural Science Foundation of China Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> (G-rant No. 81774208)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Chinese-Simplified, English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-12-04
- Registration Date
- 2021-01-04
- Anticipated Start Date
- 2021-01-01
- Anticipated Completion Date
- 2021-03-01
- Title Cn
- 芪苈强心胶囊联合西药治疗慢性心力衰竭的疗效和安全性：系统评价与Meta分析的研究方案
- Title En
- Efficacy and safety of Qili Qiangxin Capsule combined with western medicine in the treatment of chronic heart failure : Study protocol for systematic review and meta-analyses
- Bilingual Status
- complete